Agaricus blazei Mushroom (Agaricus subrufescens) — Almond Mushroom
The almond mushroom — sold commercially as Agaricus blazei Murill (ABM) and known in Brazil as the “sun mushroom” and in Japan as himematsutake — is a culinary-medicinal fungus prized for its sweet, almond-anise aroma and for cell-wall beta-glucans that activate the innate immune system in laboratory and animal studies. It is one of the most heavily marketed mushrooms in the world, yet the evidence behind it is uneven: strong in cell and animal models, modest and preliminary in people. This page explains what is reasonably well supported, what is still speculative, and the real safety considerations — including the natural compound agaritine and case reports of severe liver injury — that any honest summary must include.
Table of Contents
Overview
Agaricus blazei is a gilled mushroom in the same genus as the common white button and portobello (Agaricus bisporus). What sets it apart commercially is its reputation as an immune-supporting health food, built largely on Japanese laboratory research from the 1980s and 1990s. Like many medicinal mushrooms — Reishi, Turkey Tail, Maitake — its signature actives are polysaccharides, especially beta-glucans, that the immune system recognizes as “non-self” patterns and responds to by mobilizing defensive cells.
It is important to set expectations honestly. The most robust data are preclinical (cell cultures and rodents): in those models, Agaricus extracts activate macrophages, natural killer (NK) cells, and dendritic cells. Human evidence is limited — a small number of clinical and immunologic studies, several from a single research group, plus quality-of-life data in cancer patients undergoing chemotherapy. None of this establishes Agaricus as a treatment for any disease. It is best understood as a food-grade mushroom with measurable immunologic activity and a plausible — but unproven — supportive role.
Names & Taxonomy
The naming around this mushroom is genuinely confusing, and getting it right matters when you read labels or search the literature.
- “Agaricus blazei Murill” / “ABM” — the popular commercial name, used on nearly all products and in most older papers.
- Agaricus subrufescens Peck (1893) — the correct, accepted scientific name. Taxonomists determined that the mushroom cultivated and sold as “A. blazei” is in fact this older species. The name “A. blazei” in the strict sense refers to a different North American mushroom.
- Agaricus brasiliensis — a name proposed in the early 2000s for the cultivated strain; now treated as a synonym of A. subrufescens.
In plain terms: ABM, “Agaricus blazei,” Agaricus subrufescens, and Agaricus brasiliensis all refer to the same cultivated mushroom. This page uses the familiar “Agaricus blazei” for readability while noting that A. subrufescens is the botanically correct name. The common English name almond mushroom comes from its distinctive sweet, marzipan-like (almond / anise / benzaldehyde) aroma.
Traditional & Modern Use
Unlike Reishi or many herbs, Agaricus blazei does not have a long Asian medicinal tradition, and it is not part of Ayurveda. Its story is much more recent and is essentially a Brazilian + Japanese health-food phenomenon.
The mushroom grows wild in the mountainous Piedade region of São Paulo state, Brazil, where it earned folk names such as Cogumelo do Sol (“mushroom of the sun”) and Cogumelo de Deus (“mushroom of God”) for its reputed health-giving qualities. In the 1960s–70s samples were sent to Japan, where researchers cultivated it and gave it the names himematsutake and kawariharatake. Japanese laboratory studies on its polysaccharides drove a commercial boom, and Brazil and Japan remain the major producers and consumers.
Today it is taken almost entirely as a dietary supplement or functional food — dried powder, capsules, or hot-water extracts — rather than as a traditional remedy with codified preparation rules. Honest framing matters here: claims that wrap Agaricus in ancient-medicine language are marketing, not history.
Active Compounds
The biological activity attributed to Agaricus blazei centers on a few classes of molecules:
- Beta-glucans — the headline actives. Agaricus is notable for highly branched (1→6)-(1→3)-beta-D-glucans, a branching pattern thought to make them especially good at engaging immune receptors such as Dectin-1 and complement receptor 3. These water-soluble polysaccharides are why hot-water extracts are the preferred preparation.
- Other polysaccharides and proteoglycans — including mannans and protein-bound polysaccharide complexes that also show immunologic activity in models.
- Ergosterol and ergosterol derivatives — the fungal version of a sterol; the precursor to vitamin D2 and the subject of antioxidant and anti-angiogenic research.
- Blazein — a steroid isolated from the mushroom that induced apoptosis (programmed cell death) in human lung and stomach cancer cell lines in laboratory work — a cell-culture finding, not a clinical result.
- Agaritine — an aromatic hydrazine derivative found across the genus Agaricus (including button mushrooms). It is relevant to safety rather than benefit, and is discussed below; cooking and processing reduce its levels.
Immune Modulation
Immune modulation is the best-characterized property of Agaricus blazei, and the mechanism is well established in the laboratory. Beta-glucans are recognized by pattern-recognition receptors on innate immune cells; binding triggers activation of:
- Macrophages — increased phagocytosis and release of signaling cytokines;
- Natural killer (NK) cells — enhanced cytotoxic activity against abnormal or infected cells;
- Dendritic cells — maturation and improved antigen presentation, which bridges innate and adaptive immunity.
In cell and animal studies this translates into shifts in cytokine output (for example interferon-gamma and various interleukins). A review by Mizuno and colleagues catalogs the immunomodulating compounds of basidiomycete mushrooms including Agaricus, and a comprehensive review by Hetland and colleagues summarizes how ABM extracts modulate innate immunity in experimental models. The crucial caveat: most of this is preclinical. Human immunologic data exist but are limited in size and number, and changes in a lab marker do not automatically mean a clinical benefit.
Cancer-Care Quality of Life
This is the area most prone to overstatement, so it deserves careful framing. The most cited human study is a controlled trial by Ahn and colleagues (2004) in 100 women with cervical, ovarian, or endometrial cancer who were receiving carboplatin with etoposide or with paclitaxel every 3 weeks for at least three cycles. The 39 who took an Agaricus blazei Murill extract by mouth alongside their chemotherapy showed significantly higher natural killer-cell activity than the 61 who did not (P < 0.002), with no significant difference in lymphokine-activated killer or monocyte activity or in counts of specific immune cells. Chemotherapy-associated side effects — appetite, hair loss (alopecia), emotional stability and general weakness — were all improved in the extract group.
What this does — and does not — mean:
- It supports a possible adjunctive, supportive role: better tolerance of chemotherapy and an immunologic signal (natural killer activity).
- It is NOT evidence that Agaricus treats or shrinks cancer. The study did not test tumor response or survival, the sample was small, and findings have not been confirmed in large independent trials.
- Laboratory findings on isolated compounds (such as blazein causing apoptosis in cancer cell lines) are mechanistic curiosities, not clinical proof.
A second, randomised and double-blind trial (2015) gave 40 people with multiple myeloma who were undergoing high-dose chemotherapy and stem-cell transplant either an extract containing 82% Agaricus blazei (19 patients) or placebo (21 patients) for about seven weeks. The extract changed several immune measures, including higher percentages of regulatory T cells and plasmacytoid dendritic cells and higher blood levels of some interleukins, but “There were no statistically significant differences in treatment response, overall survival, and time to new treatment.”
In these trials Agaricus was given only as a possible supportive addition alongside cancer treatment, never as a substitute for it. The liver-safety notes below matter here, since the people in the supportive trial were themselves receiving liver-stressing chemotherapy and the liver-injury case reports involved people with advanced cancer.
Antioxidant & Anti-inflammatory
Agaricus blazei extracts show antioxidant activity in standard chemical assays, attributed in part to phenolic compounds and to ergosterol-related sterols. A food-science study by Corrêa and colleagues optimized extraction of an ergosterol-based ingredient from Agaricus blazei, documented its bioactive (including antioxidant) properties, and incorporated it into yogurt — illustrating the food-ingredient angle rather than a therapeutic claim.
On the anti-inflammatory side, the same beta-glucan–driven immune modulation that activates defenses can also help rebalance over-active inflammatory signaling in some models, and a hydroalcoholic extract was gastroprotective against ethanol-induced gastric ulcers in mice (Câmara Neto and colleagues). These are encouraging but preclinical signals; human anti-inflammatory outcome data are lacking.
Allergy & Th1/Th2 Modulation
A recurring theme in Agaricus research is the idea of rebalancing the immune system rather than simply revving it up. The immune response can lean toward a Th1 profile (cell-mediated, antiviral/antitumor) or a Th2 profile (antibody-driven, and over-active in allergy). The review by Hetland and colleagues describes how ABM appears, in experimental settings, to nudge an over-active Th2 (allergic) skew back toward Th1, with potential relevance to allergy and inflammation.
This is a genuinely interesting hypothesis with a plausible mechanism, and the supporting evidence is mostly animal and in-vitro, with one small human trial. In that 2019 randomised, placebo-controlled, double-blind trial, 60 blood donors with IgE-positive birch-pollen allergy and/or asthma took an Agaricus-based extract or placebo by mouth for 7 weeks before the pollen season; “general allergy and asthma symptoms and medication were significantly reduced” in the extract group during the season, along with lower levels of birch-pollen-specific IgE (the allergy antibody). One small trial does not establish Agaricus as an allergy treatment in people. It is included here because the Th1/Th2 framing is central to how researchers think about the mushroom — not because the clinical case is settled.
Cardiometabolic, Blood Sugar & Liver
Animal studies hint at cardiometabolic effects. De Miranda and colleagues reported a hypolipidemic (cholesterol-lowering) effect of edible Agaricus blazei in rats fed a high-cholesterol diet, and various rodent studies suggest possible improvements in glucose handling — consistent with the general metabolic effects of mushroom fiber and beta-glucan. One small human trial exists: in a 2007 randomised, double-blind, placebo-controlled trial, 72 people with type 2 diabetes already taking gliclazide and metformin received 1500 mg of Agaricus blazei extract or placebo daily for 12 weeks. At the end, insulin resistance measured by the homeostasis model assessment (HOMA-IR) was lower in the extract group (3.6 versus 6.6, p = 0.04), and the blood hormone adiponectin rose 20.0% in the extract group while it fell 12.0% on placebo (p < 0.001). Blood-sugar effects raise a practical point: combining Agaricus with diabetes medication could have additive glucose-lowering effects. Low blood sugar shows as shakiness, sweating and confusion.
The liver is the most important — and most double-edged — organ in the Agaricus story. Some research explores protective or beneficial metabolic effects (for example da Silva and colleagues studied beta-glucan effects on gene expression and metabolism in HepG2 liver cells). At the same time, case reports of severe liver injury have been linked to Agaricus blazei extract, covered directly in the safety section. Overall the cardiometabolic and liver picture is mixed and preclinical-leaning, and the liver-injury case reports are its most serious finding.
Forms & Dosage
Because the prized actives are water-soluble beta-glucans, the most evidence-aligned preparations are extracts and well-processed powders:
- Hot-water extracts — concentrate beta-glucans and are the form most used in research; often standardized to a beta-glucan percentage.
- Dried fruiting-body powder / capsules — whole-mushroom material; potency depends on the raw material and processing.
- Liquid extracts and combination “mushroom complex” products — common in the supplement market; quality varies widely.
There is no established, evidence-based therapeutic dose. Supplement labels commonly suggest on the order of 1–3 grams of extract or powder daily, and the Ahn quality-of-life study used a specific commercial extract at the manufacturer’s dose. Facts relevant to products: beta-glucan content varies between products, and only some disclose it; mushrooms readily concentrate heavy metals from their growing medium, which is why some products are third-party tested for metals and contaminants; and cooking, drying and hot-water extraction lower agaritine levels (see Safety & Cautions).
Safety & Cautions
Agaricus blazei is widely consumed as a food and is generally well tolerated, but several real cautions belong on any honest page:
- Agaritine. Like other Agaricus mushrooms, Agaricus blazei naturally contains agaritine, an aromatic hydrazine derivative with genotoxic potential in some laboratory tests. Levels fall substantially with cooking, drying, and hot-water extraction, which is one reason raw, unprocessed mushroom powder is less desirable than cooked or extracted material. The Firenzuoli review specifically examines these pharmaco-toxicological questions.
- Liver injury (hepatotoxicity). There are case reports of severe hepatic dysfunction associated with Agaricus blazei extract. Mukai and colleagues (2006) described three patients with advanced cancer, all taking Agaricus blazei extract, who developed severe liver damage; two died of fulminant hepatitis. In one patient, liver function recovered after she stopped the extract and worsened again when she restarted it. The authors wrote that, although other causes could not be completely ruled out, “a strong causal relationship between the Agaricus blazei extract and liver damage was suggested.” How often this happens is not known. The case reports raise a concern for people with liver disease, on other liver-stressing drugs, or on chemotherapy; jaundice (yellowing of the skin or eyes), dark urine and unexplained fatigue are signs of liver injury that hospitals treat as urgent.
- Autoimmune conditions and immunosuppressants. An immune-activating mushroom is theoretically unhelpful for people with autoimmune disease and could in theory counteract immunosuppressant medication (for example after transplant, or for autoimmune therapy). This concern is theoretical, not drawn from an interaction study.
- Diabetes medication. Possible additive blood-sugar lowering. The one diabetes trial gave the extract alongside gliclazide and metformin; its abstract does not report on low blood sugar.
- Pregnancy, breastfeeding, and children. Insufficient safety data.
- Contaminants. Mushrooms concentrate heavy metals from their growing medium; some products are tested for them and others are not.
Educational disclaimer: This page is for general information only and is not medical advice, diagnosis, or treatment. Agaricus blazei is not an approved treatment for any disease, and the human evidence for most claimed benefits is limited or preliminary. The concerns above apply most to people with liver disease or an autoimmune condition, people who are pregnant or breastfeeding, people receiving cancer treatment, and people taking prescription medication including immunosuppressants or diabetes drugs.
Key Research Papers
Selected peer-reviewed literature. Links resolve to PubMed or DOI.
- Ahn WS, et al. Natural killer cell activity and quality of life were improved by consumption of a mushroom extract, Agaricus blazei Murill Kyowa, in gynecological cancer patients undergoing chemotherapy. Int J Gynecol Cancer. 2004;14(4):589-94. — PubMed PMID: 15304151
- Hetland G, et al. The Mushroom Agaricus blazei Murill Elicits Medicinal Effects on Tumor, Infection, Allergy, and Inflammation through Its Modulation of Innate Immunity and Amelioration of Th1/Th2 Imbalance and Inflammation. Adv Pharmacol Sci. 2011;2011:157015. — PubMed PMID: 21912538
- Mizuno M, et al. Immunomodulating compounds in Basidiomycetes. J Clin Biochem Nutr. 2013;52(3):202-7. — PubMed PMID: 23704809
- Firenzuoli F, et al. The Medicinal Mushroom Agaricus blazei Murrill: Review of Literature and Pharmaco-Toxicological Problems. Evid Based Complement Alternat Med. 2008;5(1):3-15. — PubMed PMID: 18317543
- Mukai H, et al. An alternative medicine, Agaricus blazei, may have induced severe hepatic dysfunction in cancer patients. Jpn J Clin Oncol. 2006;36(12):808-10. — PubMed PMID: 17105737
- da Silva AF, et al. Effects of β-glucan extracted from Agaricus blazei on the expression of ERCC5, CASP9, and CYP1A1 genes and metabolic profile in HepG2 cells. Hum Exp Toxicol. 2013;32(6):647-54. — PubMed PMID: 23424205
- Itoh H, et al. Blazein of a new steroid isolated from Agaricus blazei Murrill (himematsutake) induces cell death and morphological change indicative of apoptotic chromatin condensation in human lung cancer LU99 and stomach cancer KATO III cells. Oncol Rep. 2008;20(6):1359-61. — PubMed PMID: 19020714
- de Miranda AM, et al. Hypolipidemic effect of the edible mushroom Agaricus blazei in rats subjected to a hypercholesterolemic diet. J Physiol Biochem. 2014;70(1):215-24. — PubMed PMID: 24203633
- Corrêa RCG, et al. A natural food ingredient based on ergosterol: optimization of the extraction from Agaricus blazei, evaluation of bioactive properties and incorporation in yogurts. Food Funct. 2018;9(3):1465-1474. — PubMed PMID: 29488518
- Câmara Neto JF, et al. Gastroprotective effect of hydroalcoholic extract from Agaricus blazei Murill against ethanol-induced gastric ulcer in mice. J Ethnopharmacol. 2022;292:115191. — PubMed PMID: 35292374
- Hsu CH, et al. The mushroom Agaricus Blazei Murill in combination with metformin and gliclazide improves insulin resistance in type 2 diabetes: a randomized, double-blinded, and placebo-controlled clinical trial. J Altern Complement Med. 2007;13(1):97-102. — PubMed PMID: 17309383
- Mahmood F, et al. Agaricus blazei-Based Mushroom Extract Supplementation to Birch Allergic Blood Donors: A Randomized Clinical Trial. Nutrients. 2019;11(10):2339. — PubMed PMID: 31581605
- Tangen JM, et al. Immunomodulatory effects of the Agaricus blazei Murrill-based mushroom extract AndoSan in patients with multiple myeloma undergoing high dose chemotherapy and autologous stem cell transplantation: a randomized, double blinded clinical study. Biomed Res Int. 2015;2015:718539. — PubMed PMID: 25664323